RxDoctor Payments Data

Tung Nguyen, DO

Family Medicine · Mableton, GANPI 1245248103

Payments from drug & device makers

$780in general payments, 2019–2025

Across 54 payments — averaging $14.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$144
  • Amgen$136
  • Novo Nordisk$119
  • Pfizer$94
  • Boehringer Ingelheim$67
  • Lilly USA, LLC$56
  • plus $164 from 7 others

What the payments were for

  • Food & beverage$77499%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$780 in reported general payments places this provider in the 55th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$64,452
Medicare patients
198
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide156$189,146
FarxigaDapagliflozin Propanediol64$69,964
TrulicityDulaglutide44$58,277
JardianceEmpagliflozin43$53,014
JanuviaSitagliptin Phosphate41$51,114
ProliaDenosumab29$49,788
EliquisApixaban26$28,188
MyrbetriqMirabegron13$14,758
RybelsusSemaglutide11$14,238
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,833
Tresiba Flextouch U-100Insulin Degludec13$9,048
Breo ElliptaFluticasone/Vilanterol15$8,081
LinzessLinaclotide14$7,448
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$4,650
Levemir FlexpenInsulin Detemir19$4,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$119$203,385167 claims
AstraZenecaFarxiga$144$69,96464 claims
Lilly USA, LLCTrulicity$56$58,27744 claims
Boehringer IngelheimJardiance$67$53,01443 claims
AmgenProlia$136$49,78829 claims
PfizerEliquis$94$28,18826 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$32$26,56546 claims
Astellas Pharma US IncMyrbetriq$18$14,75813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Mableton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →